Advanced Filter

Filter by Group

Filter by Market Availability

Displaying 1 drug
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha).It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to...
Approved
Matched Description: … [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L4894] and updated ... [A176606] Certolizumab does not require glycosylation for active function and hence, its production ... The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Displaying 1 drug